Zongertinib was granted accelerated approval as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer with HER2-activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence) in combination with venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or...
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The U.S. Food and Drug Administration (FDA) approved Optune Pax, a portable, noninvasive device for the...
Pembrolizumab plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) as well as pembrolizumab and berahyaluronidase...
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro)...
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug Administration (FDA) has approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection as an alternative...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval to rucaparib (Rubraca)...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with...
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More